Literature DB >> 15474095

Mevastatin inhibits ovarian theca-interstitial cell proliferation and steroidogenesis.

Daniel Izquierdo1, Nastaran Foyouzi, Jakub Kwintkiewicz, Antoni J Duleba.   

Abstract

OBJECTIVE: Statins reduce cardiovascular risks by improving hypercholesterolemia, reducing vascular smooth muscle proliferation, and ameliorating inflammation. Polycystic ovary syndrome (PCOS) is associated with increased cardiovascular risks and is characterized by ovarian theca-interstitial hyperplasia and hyperandrogenism. This study tested the hypothesis that mevastatin limits theca-interstitial proliferation and decreases steroidogenesis.
DESIGN: In vitro study.
SETTING: Academic laboratory. PATIENT(S): None. INTERVENTION(S): Effects of mevastatin on cultured theca-interstitial cells. MAIN OUTCOME MEASURE(S): Proliferation was evaluated by determination of DNA synthesis using thymidine incorporation assay and by 3-(4,5-dimethylthiazol-2-yl)2,5-diphenyl tetrazolium bromide (MTT) assay. Production of P and T was determined by specific radioimmunoassays. RESULT(S): Mevastatin induced a profound concentration-dependent inhibition of DNA synthesis. At the highest concentration (30 microM), mevastatin inhibited DNA synthesis by 92%. Similarly, in the MTT proliferation assay, mevastatin induced a concentration-dependent decrease in cell number. Mevastatin decreased production of P (by up to 49%) and T (by up to 52%); these effects remained significant when the effect on cell culture protein content was accounted for. CONCLUSION(S): Mevastatin inhibits proliferation of theca-interstitial cells; it also inhibits P and T production independently of the effects on cell growth. These findings provide a foundation for studies evaluating statins as potential therapeutic agents in the treatment of ovarian mesenchymal hyperplasia and hyperandrogenism characteristic of PCOS.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15474095     DOI: 10.1016/j.fertnstert.2004.03.037

Source DB:  PubMed          Journal:  Fertil Steril        ISSN: 0015-0282            Impact factor:   7.329


  23 in total

Review 1.  Emerging concepts about prenatal genesis, aberrant metabolism and treatment paradigms in polycystic ovary syndrome.

Authors:  Selma F Witchel; Sergio E Recabarren; Frank González; Evanthia Diamanti-Kandarakis; Kai I Cheang; Antoni J Duleba; Richard S Legro; Roy Homburg; Renato Pasquali; Rogerio A Lobo; Christos C Zouboulis; Fahrettin Kelestimur; Franca Fruzzetti; Walter Futterweit; Robert J Norman; David H Abbott
Journal:  Endocrine       Date:  2012-06-04       Impact factor: 3.633

2.  Inadequacy of initiating rosuvastatin then metformin on biochemical profile of polycystic ovarian syndrome patients.

Authors:  G Ghazeeri; H A Abbas; B Skaff; S Harajly; J Awwad
Journal:  J Endocrinol Invest       Date:  2015-02-27       Impact factor: 4.256

3.  Effects of simvastatin and metformin on polycystic ovary syndrome after six months of treatment.

Authors:  Beata Banaszewska; Leszek Pawelczyk; Robert Z Spaczynski; Antoni J Duleba
Journal:  J Clin Endocrinol Metab       Date:  2011-08-24       Impact factor: 5.958

4.  Antileishmanial effect of mevastatin is due to interference with sterol metabolism.

Authors:  Neeradi Dinesh; Neelagiri Soumya; Sushma Singh
Journal:  Parasitol Res       Date:  2015-07-18       Impact factor: 2.289

5.  Simvastatin reduces steroidogenesis by inhibiting Cyp17a1 gene expression in rat ovarian theca-interstitial cells.

Authors:  Israel Ortega; Amanda B Cress; Donna H Wong; Jesus A Villanueva; Anna Sokalska; Ben C Moeller; Scott D Stanley; Antoni J Duleba
Journal:  Biol Reprod       Date:  2012-01-30       Impact factor: 4.285

6.  The effects of old, new and emerging medicines on metabolic aberrations in PCOS.

Authors:  Alexandra Bargiota; Evanthia Diamanti-Kandarakis
Journal:  Ther Adv Endocrinol Metab       Date:  2012-02       Impact factor: 3.565

7.  Evidence for statin therapy in polycystic ovary syndrome.

Authors:  Thozhukat Sathyapalan; Stephen L Atkin
Journal:  Ther Adv Endocrinol Metab       Date:  2010-02       Impact factor: 3.565

8.  Role of isoprenylation in simvastatin-induced inhibition of ovarian theca-interstitial growth in the rat.

Authors:  Izabela J Rzepczynska; Piotr C Piotrowski; Donna H Wong; Amanda B Cress; Jesus Villanueva; Antoni J Duleba
Journal:  Biol Reprod       Date:  2009-07-01       Impact factor: 4.285

9.  Comparison of simvastatin and metformin in treatment of polycystic ovary syndrome: prospective randomized trial.

Authors:  Beata Banaszewska; Leszek Pawelczyk; Robert Z Spaczynski; Antoni J Duleba
Journal:  J Clin Endocrinol Metab       Date:  2009-11-04       Impact factor: 5.958

10.  Variants in the HMG-CoA reductase (HMGCR) gene influence component phenotypes in polycystic ovary syndrome.

Authors:  Ning Xu; Kent D Taylor; Ricardo Azziz; Mark O Goodarzi
Journal:  Fertil Steril       Date:  2009-03-26       Impact factor: 7.329

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.